C. Blanchette

发表

Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease

L. Clark, S. Whitmire, S. Patton, 2017, Journal of medical economics.

Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function

C. Blanchette, A. Nunes, S. Johnston, 2015, Drugs in context.

Potential benefits and problems with computerized prescriber order entry: analysis of a voluntary medication error-reporting database.

C. Zhan, M. Keyes, R. Hicks, 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Quarterly Assessment of Short-Acting β2-Adrenergic Agonist Use as a Predictor of Subsequent Health Care Use for Asthmatic Patients in the United States

C. Blanchette, B. Gutierrez, H. Silver, 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis.

C. Blanchette, F. Ernst, C. Roberts, 2010, Clinical therapeutics.

Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers.

Akshay Sood, A. Sood, S. Belinsky, 2010, American journal of respiratory and critical care medicine.

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

C. Blanchette, B. Gutierrez, A. Eramo, 2016, Drugs in context.

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.

S. Simoens, C. Pashos, C. Blanchette, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer

C. Blanchette, R. Howden, S. Arthur, 2019, International journal of chronic obstructive pulmonary disease.

COPD_A_185837 893..903

C. Blanchette, R. Howden, S. Arthur, 2019 .

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

D. Lubeck, S. Rossetti, C. Blanchette, 2015, Drugs in context.

Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease

S. Rossetti, C. Blanchette, B. Gutierrez, 2014 .

Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US

D. Lubeck, S. Rossetti, C. Blanchette, 2015, Journal of medical economics.

Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies

Anand A. Dalal, T. Delea, C. Blanchette, 2009, Current medical research and opinion.

Appropriate use of inhaled corticosteroid and long-acting ß2-adrenergic agonist combination therapy among asthma patients in a US commercially insured population

C. Blanchette, B. Gutierrez, M. Nelson, 2009, Current medical research and opinion.

End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases

A. Claxton, S. Rossetti, C. Blanchette, 2015, ClinicoEconomics and outcomes research : CEOR.

Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

C. Blanchette, B. Gutierrez, K. Friend, 2014, Annals of Internal Medicine.

Depression Following Thrombotic Cardiovascular Events in Elderly Medicare Beneficiaries: Risk of Morbidity and Mortality

C. Blanchette, B. Stuart, F. Shaya, 2009, Cardiology research and practice.

Adherence to controller therapy for chronic obstructive pulmonary disease: a review

Anand A. Dalal, D. Lavallee, C. Blanchette, 2010, Current medical research and opinion.

COPD_A_263297 2389..2397

C. Blanchette, R. Howden, R. Sandhaus, 2020 .

Burden of blood transfusion in knee and hip surgery in the US and Belgium

C. Blanchette, M. Szpalski, R. Gunzburg, 2009, Journal of medical economics.

The value of self-medication: summary of existing evidence

C. Blanchette, J. Noone, 2018, Journal of medical economics.

Assessing disparities in the receipt of inhaled corticosteroid prescriptions for asthma by Hispanic and non-Hispanic white patients.

D. Raisch, C. Blanchette, M. Borrego, 2015, Annals of the American Thoracic Society.

Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverage.

C. Blanchette, B. Stuart, T. Shaffer, 2008, Health services research.

Cost and utilization of blood transfusion associated with spinal surgeries in the United States

Peter Kruse, C. Blanchette, A. Joshi, 2007, European Spine Journal.

One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA

C. Blanchette, J. Noone, S. Arthur, 2014, Drugs in context.

Prevalence Of Comorbidities In Patients Hospitalized For COPD Exacerbations And Impact On Impatient Mortality And Hospital Expenditures

C. Blanchette, M. Roberts, H. Silver, 2010, ATS 2010.

Moderate Symptom-Based Exacerbations as Predictors of Severe Claims-Based Exacerbations in Asthma

C. Blanchette, A. Fuhlbrigge, J. Seltzer, 2013, Journal of Asthma.

Resource utilization and costs of blood management services associated with knee and hip surgeries in US hospitals

Peter Kruse, C. Blanchette, A. Joshi, 2006, Advances in therapy.

Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.

Anand A. Dalal, C. Blanchette, L. Simoni-Wastila, 2008, The American journal of geriatric pharmacotherapy.

Hospital and emergency department utilization associated with treatment for chronic obstructive pulmonary disease in a managed-care Medicare population

Anand A. Dalal, C. Blanchette, J. Qian, 2009, Current medical research and opinion.

Wood Smoke-Associated Chronic Obstructive Pulmonary Disease (COPD) – Underappreciated in the United States?.

A. Sood, S. Belinsky, Y. Tesfaigzi, 2009, ATS 2009.

One-year Prevalence, Comorbidities, and Cost of Hospitalizations for Alpha-1 Antitrypsin Deficiency among Patients with Chronic Obstructive Pulmonary Disease in the United States

C. Blanchette, R. Howden, D. Roy, 2017 .

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy

C. Blanchette, J. Russell, V. Bril, 2016, Journal of diabetes and its complications.

Relationship between short-acting β2-adrenergic agonist use and healthcare costs.

C. Blanchette, B. Gutierrez, H. Silver, 2011, The American journal of managed care.

Cachexia among US cancer patients

C. Blanchette, J. Noone, S. Arthur, 2016, Journal of medical economics.

PRS1 BURDEN OF CONCOMITANT ASTHMA AND COPD IN A MEDICAID POPULATION

C. Blanchette, F. Shaya, D. Mapel, 2007 .

Cost-Effectiveness of Fluticasone Propionate/Salmeterol (250/50mcg) Compared to Salmeterol (50mcg) in Patients with Chronic Obstructive Pulmonary Disease: Economic Evaluation of Study SCO100250.

Anand A. Dalal, C. Blanchette, H. Petersen, 2009, ATS 2009.

COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE/SALMETEROL (250/50 MCG) COMPARED TO SALMETEROL (50 MCG) IN PATIENTS WITH COPD: ECONOMIC EVALUATION OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER TRIAL (STUDY SCO40043)

Anand A. Dalal, C. Blanchette, H. Petersen, 2008 .

Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.

C. Blanchette, R. Stanford, M. Akazawa, 2008, The American journal of managed care.

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Anand A. Dalal, C. Blanchette, G. Ferguson, 2011, International journal of chronic obstructive pulmonary disease.

Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.

C. Blanchette, R. Howden, J. Noone, 2019, American health & drug benefits.

Spatial Analysis of Health Care Utilization among Medicare Beneficiaries with Coal Workers’ Pneumoconiosis and Other Related Pneumoconiosis

C. Blanchette, T. Borders, R. Paul, 2021 .

Comparison between spinal surgery blood transfusion services costs and associated treatment practices in the United States and Belgium

C. Blanchette, M. Szpalski, R. Gunzburg, 2007, Current medical research and opinion.

Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals.

M. Raebel, David H. Smith, C. Blanchette, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia.

C. Blanchette, B. Gutierrez, D. Strutton, 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population.

C. Blanchette, B. Stuart, I. Zuckerman, 2008, Annals of epidemiology.

Evaluating cost benefits of combination therapies for advanced melanoma

C. Blanchette, Jie Zhang, I. Jensen, 2016, Drugs in context.

A Continuous Publication, Open Access, Peer-reviewed Journal

C. Blanchette, Jie Zhang, I. Jensen, 2022 .

Effect of combination fluticasone propionate and salmeterol or inhaled corticosteroids on asthma-related outcomes in a Medicare-eligible population.

C. Blanchette, A. Fuhlbrigge, R. Stanford, 2012, The American journal of geriatric pharmacotherapy.

Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids’ Inpatient Database

C. Blanchette, J. Noone, S. Arthur, 2015, Drugs in context.

Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring

M. Raebel, D. Roblin, David H. Smith, 2010, Journal of General Internal Medicine.

Incidence and Cost of Ankle Sprains in United States Emergency Departments

Shweta Shah, Abbey C. Thomas, Erik A. Wikstrom, 2016, Sports health.

Protocol for a two-arm pragmatic stepped-wedge hybrid effectiveness-implementation trial evaluating Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship (ENCOMPASS)

Michael F Dulin, D. Angus, S. Halpern, 2021, BMC Health Services Research.

Outpatient costs of medications for patients with chronic heart failure.

C. Blanchette, S. Hardin, L. Hussey, 2002, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

Burden of concomitant asthma and COPD in a Medicaid population.

Anand A. Dalal, C. Blanchette, S. Scharf, 2008, Chest.

The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD management.

Anand A. Dalal, C. Blanchette, J. S. Hurley, 2010, Primary care respiratory journal : journal of the General Practice Airways Group.

Healthcare Cost and Utilization before and after Diagnosis of Pseudomonas aeruginosa among Patients with Non-Cystic Fibrosis Bronchiectasis in the U.S.

C. Blanchette, R. Howden, J. Noone, 2017, Medical sciences.

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Anand A. Dalal, C. Blanchette, M. Roberts, 2011, International journal of chronic obstructive pulmonary disease.

Advances in chronic obstructive pulmonary disease among older adults

C. Blanchette, Christopher M. Blanchette, Susan R. Berry, 2011, Current opinion in pulmonary medicine.

From Current Opinion in Pulmonary Medicine

C. Blanchette, Sandi J. Lane, S. Berry, 2011 .

Prevalence of Depression/Anxiety among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease and Association with Acute Exacerbations

C. Blanchette, 2016 .

Economic Burden in Direct Costs of Concomitant Chronic Obstructive Pulmonary Disease and Asthma in a Medicare Advantage Population

C. Blanchette, E. Chang, B. Gutierrez, 2008, Journal of managed care pharmacy : JMCP.

Comorbidities and length of stay in chronic obstructive pulmonary disease patients

C. Ruban, C. Blanchette, Lanny S. Inabnit, 2018, COPD.

Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC

C. Blanchette, R. Howden, S. Arthur, 2018, Journal of medical economics.

The Association of COPD Exacerbations with New Onset Type 2 Diabetes among Medicare Patients

C. Ruban, C. Blanchette, J. Marino, 2017, Journal of health economics and outcomes research.

Methylated Genes in Sputum Among Older Smokers With Asthma.

A. Sood, S. Belinsky, Y. Tesfaigzi, 2012, Chest.

Changes in COPD demographics and costs over 20 years

Anand A. Dalal, C. Blanchette, D. Mapel, 2012, Journal of medical economics.

Economic burden prior to COPD diagnosis: a matched case-control study in the United States.

Anand A. Dalal, C. Blanchette, R. Stanford, 2008, Respiratory medicine.

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients

Anand A. Dalal, C. Blanchette, M. Roberts, 2010, International journal of chronic obstructive pulmonary disease.

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

N. Gross, C. Blanchette, P. Altman, 2014, American health & drug benefits.

Original article Changes in COPD demographics and costs over 20 years

Anand A. Dalal, C. Blanchette, D. Mapel, 2012 .

Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD

Anand A. Dalal, C. Blanchette, L. Simoni-Wastila, 2009, Journal of medical economics.

RESPIR ATORY EDITORIAL BOARD

C. Blanchette, A. Exuzides, K. Elward, 2015 .

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

Anand A. Dalal, C. Blanchette, M. Roberts, 2010, International journal of chronic obstructive pulmonary disease.

Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.

K. Rascati, C. Blanchette, R. Stanford, 2007, Clinical therapeutics.

Diabetes complications and adverse health outcomes after coronary revascularization.

S. Laditka, J. Studnicki, J. Laditka, 2014, Diabetes research and clinical practice.

Estimated incidence of pertussis in people aged <50 years in the United States

C. Blanchette, G. Krishnarajah, P. Buck, 2016, Human vaccines & immunotherapeutics.

Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management

C. Blanchette, S. Ramachandran, M. Roberts, 2011, Journal of medical economics.

The Relative Value of Anti-Obesity Medications Compared to Similar Therapies

C. Blanchette, C. Burudpakdee, A. Ramasamy, 2022, ClinicoEconomics and outcomes research : CEOR.

Selective cyclooxygenase-2 inhibition and cardiovascular effects: An observational study of a Medicaid population

C. Mullins, C. Blanchette, M. Weir, 2005 .

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

C. Mullins, C. Blanchette, M. Weir, 2005, Archives of internal medicine.

Direct Medical Costs for Complications Among Children and Adults with Diabetes in the US Commercial Payer Setting

K. Boye, C. Blanchette, J. Yeaw, 2014, Applied Health Economics and Health Policy.

Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy.

C. Blanchette, M. Salvati, J. Penrod, 2014 .

Health Care Cost and Utilization Associated With Alpha-1 Antitrypsin Deficiency Among A Cohort of Medicare Beneficiaries With Copd.

C. Blanchette, M. Runken, E. Zacherle, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Health care use in depressed, elderly, cardiac patients and the effect of antidepressant use.

C. Blanchette, B. Stuart, F. Shaya, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Effectiveness of Inhaled Combined Corticosteroid/Long-Acting Bronchodilator Treatment in Reducing COPD Exacerbations and Short-Acting Bronchodilator Use

C. Blanchette, S. Ramachandran, M. Roberts, 2013 .

Persistence With Testosterone Replacement Therapy

C. Blanchette, R. Puenpatom, S. Camper, 2014 .

Healthcare cost and utilization before and after diagnosis of pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the US

C. Blanchette, R. Howden, M. Runken, 2016 .

Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia.

C. Karson, H. Nasrallah, C. Blanchette, 2015, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

The positive predictive value of a hyperkalemia diagnosis in automated health care data

M. Raebel, C. Blanchette, Stanley Xu, 2010, Pharmacoepidemiology and drug safety.

Cost and utilization of COPD and asthma among insured adults in the US*

Anand A. Dalal, M. Broder, C. Blanchette, 2009, Current medical research and opinion.

Probabilistic data linkage: a case study of comparative effectiveness in COPD

C. Blanchette, M. Roberts, M. DeKoven, 2013, Drugs in context.

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US

C. Strange, C. Blanchette, R. Howden, 2020, International journal of chronic obstructive pulmonary disease.

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Anand A. Dalal, C. Blanchette, M. Roberts, 2011, International Journal of COPD.

International Journal of Copd Dovepress Comparative Cost-effectiveness of a Fluticasone- Propionate/salmeterol Combination versus Anticholinergics as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease

Anand A. Dalal, C. Blanchette, M. Roberts, 2022 .

Longer Hospitalizations, Increased Inpatient Mortality and Costs Are Associated with Alloimmunization Among Patients with Myelodysplastic Syndromes

C. Blanchette, E. Gehrie, E. Viayna, 2021, Blood.

Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.

D. DeAngelo, C. Blanchette, V. Bollu, 2009 .

Shared decision making and time to exacerbation in children with asthma

Michael F Dulin, C. Blanchette, Y. Taylor, 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

A cross-sectional retrospective analysis of the regionalization of complex surgery

J. Studnicki, C. Blanchette, S. Shahbazi, 2014, BMC Surgery.

International Journal of Chronic Obstructive Pulmonary Disease Dovepress Cost-effectiveness of Combination Fluticasone Propionate–salmeterol 250/50 Μg versus Salmeterol in Severe Copd Patients

Anand A. Dalal, C. Blanchette, M. Roberts, 2022 .

Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.

Anand A. Dalal, C. Blanchette, I. Zuckerman, 2009, The American journal of geriatric pharmacotherapy.

Burden of concomitant asthma and COPD in a Medicaid population.

Anand A. Dalal, C. Blanchette, S. Scharf, 2008, Chest.

Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis.

C. Blanchette, F. Ernst, C. Roberts, 2010, Clinical therapeutics.

Anand A. Dalal, C. Blanchette, M. Roberts, 2022 .

The positive predictive value of a hyperkalemia diagnosis in automated health care data

M. Raebel, C. Blanchette, Stanley Xu, 2010, Pharmacoepidemiology and drug safety.